It’s time to load up on Halloween candy, and while you’re at, why not start a holiday wish list? Black Friday is just a handful of weeks away and each year it seems retailers start dropping prices…
Blog
-
‘Not a distraction’: Schmidt says Wallabies have opportunity with absences
Joe Schmidt is refusing to complain about ‘unfair’ odds being stacked against his Wallabies in the Twickenham Test with England, despite being deprived of the chance to field some of his top players.
Australia’s coach…
Continue Reading
-
House of Ashur’ Red-Band Trailer Is So Very Bloody
Starz is making sure audiences know Spartacus: House of Ashur will be as bloody and sexy as fans of the franchise have come to expect. The explicit red band trailer for the series, which bows on Starz Dec. 5, arrives more than a decade…
Continue Reading
-
British health authorities warn of “unusually early” start to winter flu season-Xinhua
LONDON, Oct. 30 (Xinhua) — Britain is experiencing an unusually early start to its winter flu season, with a marked rise in cases among children and increasing activity across other age groups, the UK Health Security Agency (UKHSA) said…
Continue Reading
-
‘Only Murders In The Building’ Season 6 News & Updates
SPOILER ALERT: This piece contains spoilers for the Season 5 finale episode of Only Murders in the Building.
Another Arconia murder mystery has come and gone, but another dead body was found on the premises, though it could be argued that…
Continue Reading
-
I Played Google’s New Pac-Man Halloween Doodle: It’s a Totally Tubular ’80s Throwback
My fellow 1980s children, our old pal Pac-Man is back. And how in the world is he 45 years old already? The new Halloween Google Doodle is here to challenge us with a spooky-themed version of the classic arcade game on our computers and other…
Continue Reading
-
The Keen-Eyed Vera Rubin Observatory Has Discovered A Massive Stellar Stream
The Vera Rubin Observatory (VRO) hasn’t yet begun it’s much-anticipated Legacy Survey of Space and Time. But it saw its first light in June 2025, when it captured its Virgo First Look images as part of commisioning its main camera. Those…
Continue Reading
-
Australia’s insurance market softens as competition intensifies
The property sector is seeing an influx of local and international capacity.
Australia’s insurance market is entering a softening phase as competition increases, particularly in property and financial lines, according to WTW’s latest Global…
Continue Reading
-
Tim Cook didn't have much to say about reports of low iPhone Air sales – AppleInsider
- Tim Cook didn’t have much to say about reports of low iPhone Air sales AppleInsider
- New report claims Apple hasn’t cut iPhone Air production – GSMArena.com news GSMArena.com
- Apple’s iPhone Air doesn’t look like a bestseller. It might not matter
Continue Reading
-
Nektar Therapeutics to Participate in the Jefferies Global Healthcare Conference in London
SAN FRANCISCO, Oct. 30, 2025 /PRNewswire/ — Nektar Therapeutics (Nasdaq: NKTR) today announced that company management will be webcasting its participation in the Jefferies Global Healthcare Conference being held November 17-20, 2025 in London.
- Jefferies Global Healthcare Conference in London on Thursday, November 20, 2025 – webcast to be available at 11:00 a.m. Greenwich Mean Time / 3:00 a.m. Pacific Time – link here
The fireside chat will be accessible via the webcast link above as well as on the Investor Events section of the Nektar website: https://ir.nektar.com/events-and-presentations/events. A replay of the presentation will be available for 30 days.
If you would like to request a one-on-one meeting with company management during the conference, please reach out to your Jefferies representative.
About Nektar Therapeutics
Nektar Therapeutics is a clinical-stage biotechnology company focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. Nektar’s lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel, first-in-class regulatory T cell stimulator being evaluated in two Phase 2b clinical trials, one in atopic dermatitis, one in alopecia areata, and in one Phase 2 clinical trial in Type 1 diabetes mellitus. Nektar’s pipeline also includes a preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422. Nektar, together with various partners, is also evaluating NKTR-255, an investigational IL-15 receptor agonist designed to boost the immune system’s natural ability to fight cancer, in several ongoing clinical trials.
Nektar is headquartered in San Francisco, California. For further information, visit http://www.nektar.com and follow us on LinkedIn.
Contact:
For Investors:
Vivian Wu of Nektar Therapeutics
628-895-0661For Media:
Jonathan Pappas
LifeSci Communications
857-205-4403
[email protected]SOURCE Nektar Therapeutics
Continue Reading